Free tool
FAERS Monitor: Naproxen Sodium
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021920 or its brand name (Naproxen Sodium, Naproxen Sodium). Reports on generic versions are filed under their own applications.
Reports
66,594
Serious
27,369
41% of reports
Hospitalization
12,267
Death reported
5,059
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective11,083
- fatigue5,089
- product use issue4,788
- pain4,754
- nausea4,276
- arthralgia4,097
- headache4,062
- off label use3,990
- dizziness3,951
- diarrhoea3,946
- rash3,562
- vomiting3,466
- drug hypersensitivity3,320
- abdominal discomfort3,164
- abdominal pain upper3,139
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 644 |
| 2005 | 773 |
| 2006 | 633 |
| 2007 | 659 |
| 2008 | 3,280 |
| 2009 | 1,851 |
| 2010 | 786 |
| 2011 | 1,013 |
| 2012 | 1,808 |
| 2013 | 1,570 |
| 2014 | 3,690 |
| 2015 | 7,074 |
| 2016 | 6,846 |
| 2017 | 5,779 |
| 2018 | 4,834 |
| 2019 | 4,632 |
| 2020 | 3,587 |
| 2021 | 3,017 |
| 2022 | 2,928 |
| 2023 | 2,813 |
| 2024 | 3,527 |
| 2025 | 3,243 |
| 2026 | 1,605 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,987,565 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product use issueSignal | 4,788 | 8.2 | 8.0 | 29,899 |
| abdominal discomfortSignal | 3,164 | 6.1 | 5.8 | 13,193 |
| drug hypersensitivitySignal | 3,320 | 5.5 | 5.3 | 12,107 |
| abdominal pain upperSignal | 3,139 | 4.9 | 4.7 | 9,609 |
| arthralgiaSignal | 4,097 | 3.1 | 3.0 | 6,008 |
| drug ineffectiveSignal | 11,083 | 2.7 | 2.6 | 12,245 |
| rashSignal | 3,562 | 2.6 | 2.5 | 3,532 |
| dizzinessSignal | 3,951 | 2.5 | 2.4 | 3,659 |
| painSignal | 4,754 | 2.5 | 2.4 | 4,191 |
| vomitingSignal | 3,466 | 2.3 | 2.3 | 2,694 |
| fatigueSignal | 5,089 | 2.1 | 2.0 | 2,909 |
| headacheSignal | 4,062 | 2.1 | 2.0 | 2,246 |
| diarrhoea | 3,946 | 1.9 | 1.9 | 1,831 |
| nausea | 4,276 | 1.7 | 1.7 | 1,303 |
| off label use | 3,990 | 1.4 | 1.4 | 559 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.